๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Relapsed or Refractory Multiple Myeloma
Clinical trial register · China

Relapsed or Refractory Multiple Myeloma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tianjin 3
Narrow the registerReset
Recruitment status
Phase
Site location
Tianjin3
All 1 locations
Target enrolment
to

Relapsed or Refractory Multiple Myeloma trials in China

3 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
NCT07018050Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 2
160
Tianjin
2025-09-12
Not yet open
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
NCT06500507Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 1
90
Tianjin
2024-08-30
Rows per page Showing 1–3 of 3
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/relapsed-or-refractory-multiple-myeloma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3 of those studies listing the condition Relapsed or Refractory Multiple Myeloma that also match the filters currently applied.

How many Relapsed or Refractory Multiple Myeloma trials are recruiting in China?

2 of the 3 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Relapsed or Refractory Multiple Myeloma), 3 studies
PhaseStudiesRecruitingShare
Phase 11033.3%
Phase 21133.3%
Phase 31133.3%

Most active sponsors

Lead sponsors with the most studies (Relapsed or Refractory Multiple Myeloma)
Lead sponsorStudiesRecruiting
Qilu Pharmaceutical Co., Ltd.32
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.